Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 1/2010

01-01-2010 | Drug Reactions and Interactions

Glitazones accelerate bone loss and increase the risk of fracture in patients with type 2 diabetes mellitus

Published in: Drugs & Therapy Perspectives | Issue 1/2010

Login to get access

Excerpt

Thiazolidinediones, which are commonly known as glitazones, are used in the treatment of type 2 diabetes mellitus. Through their activation of peroxisome proliferator-activated receptor-γ nuclear transcription factor, glitazones may decrease bone formation, leading to decreased bone mineral density and an increased risk of fractures, particularly in women. Currently, there are no data on whether any treatments mitigate glitazone-induced adverse skeletal effects. …
Literature
1.
Bodmer M, Meier C, Kraenzlin ME, et al. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009; 32(7): 539–47PubMedCrossRef
2.
Okazaki R, Miura M, Toriumi M, et al. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 1999; 46(6): 795–801PubMedCrossRef
3.
Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007 Sep; 92(9): 3523–30PubMedCrossRef
4.
Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92(4): 1305–10PubMedCrossRef
5.
Glintborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93(5): 1696–701PubMedCrossRef
6.
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180(1): 32–9PubMedCrossRef
7.
Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168(8): 820–5PubMedCrossRef
8.
Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30(6): 1574–6PubMedCrossRef
9.
Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009; 169(15): 1395–402PubMedCrossRef
10.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125–35PubMedCrossRef
11.
Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31(5): 845–51PubMedCrossRef
Metadata
Title
Glitazones accelerate bone loss and increase the risk of fracture in patients with type 2 diabetes mellitus
Publication date
01-01-2010
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 1/2010
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.2165/11203640-000000000-00000

Other articles of this Issue 1/2010

Drugs & Therapy Perspectives 1/2010 Go to the issue

Disease Management

Aggressive treatment is essential to reduce cardiovascular risk in diabetic hypertensive patients

Drug and Profile Reports

Fesoterodine: a guide to its use in overactive bladder syndrome

Practical Issues and Updates

News from the 38th European Symposium on Clinical Pharmacy; 3–6 November 2009; Geneva

Disease Management

Worldwide control of trachoma involves a strategy combining surgery, antibacterials, facial cleanliness and environmental improvements

Disease Management

Antidepressants are the main options for the long-term pharmacological treatment of generalized anxiety disorder

Drug and Profile Reports

Ferric carboxymaltose: a guide to its use in iron-deficiency anaemia